Lipid Analysis
MIN, TG
OSTEOPOROSIS
The changes in serum lipid metabolites before and after the treatment are shown in Fig. Changes in serum levels of lipid markers before and after the treatment. Both treatment groups showed significant decline in lipid marker levels except for serum level of HDL-C. The RLX-treated group showed significantly larger decline in TC, LDL-C, and TG than the MIN-treated group. A total of 745 out of 3246 (23%) cases (377 for RLX and 368 for MIN) were treated with statins prior to the start of the observation. There was no significant difference in concurrent statin use between the two groups. The changes in LDL-C levels in both groups, with or without statin use, are depicted in Fig. Changes in serum level of LDL cholesterol in the patients with or without statin use. A total of 745 patients out of 3246 participants (377 for RLX and 368 for MIN) were treated with statins prior to start the treatment of osteoporosis. The subjects were divided into four groups in accordance with the treatment received, and depending on statin use. The baseline LDL-C levels with statin users showed significantly lower baseline LDL-C levels. Serum LDL-C levels after the treatment with MIN or RLX indicated a significant decrease at 6 and 24 months treatment regardless of statin use. 